Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05653427 |
| Consolidated Lead Sponsor | Johnson & Johnson / Janssen |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 18 participants (ACTUAL) |
| Registered Start Date | 2022-12-08 |
| WhyStopped Classification | Lack of Efficacy / Futility |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Beijing Cancer Hospital | Beijing, China | Open Hospital Dossier -> |
| Chongqing Cancer Hospital | Chongqing, China | Open Hospital Dossier -> |
| Zhejiang Cancer Hospital | Hangzhou, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.